News Center

Claudin 18.2 ADC LM-302 obtained FDA Orphan Drug Designation in May 2021 for indications of pancreatic, gastric, and gastroesophageal junction cancers.

In November 2020, LaNova Medicines completed the series A financing with Qiming Venture Partners as the leading investor and China Renaissance as the financial adviser. Investors also include global or domestic well-known PE / VCs, such as TF Capital, Yin